Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
36.92%
Operating Margin
30.73%
Net Margin
35.43%
Efficiency Metrics
Revenue per Expense Ratio
1.44
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
73.94%
Income Tax Rate
21.62%
EPS
10.8500000000
Balance Sheet Analysis
Current Ratio
2.61
Cash Ratio
1.43
Working Capital
$23.77B
Debt to Equity
1.84
Debt to Assets
57.23%
Equity Ratio
31.12%
Cash Flow Analysis
Operating Cash Flow Ratio
43.67%
Free Cash Flow Ratio
-0.50%
CapEx to Revenue
44.16%
Dividends Paid
$192.53M
Stock Buybacks
$880.91M
Total Shareholder Returns
$1.07B
Cash Position Change
-12.20%
Key Takeaways (2023 FY)
Revenue declined by 20.219104409537%, indicating potential market challenges
Detailed Growth Metrics
Core Performance
Revenue
-20.22%
Net Income
-39.76%
EPS
-38.28%
Operating Income
-45.03%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
-17.75%
Operating Cash Flow
-19.99%
Free Cash Flow
-103.55%
Balance Sheet Health
Assets
7.80%
Debt
3.29%
Book Value per Share
38.50%
Inventory
3.82%
Shareholder Returns
Dividends per Share
-95.25%
Shares Outstanding
-2.45%
Long Term Trends
3Y Revenue/Share
35.70%
5Y Revenue/Share
149.19%
3Y Dividend/Share
0.00%
5Y Dividend/Share
-22.82%